Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.47 |
| ▸ | CCR5 | P51681 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6409742 | 0.93 | ROCK2 (0.47) | ROCK2ROCK1CCR5ALDH1A1MMP1 | |
| Hydrochloric Acid SCHEMBL6409741 | 0.92 | ROCK2 (0.46) | ROCK2ROCK1CCR5ALDH1A1MMP1 | |
| SCHEMBL6411551 | 0.92 | ROCK2 (0.44) | ROCK2ROCK1CCR5ALDH1A1MMP1 | |
| Hydrochloric Acid SCHEMBL6411547 | 0.91 | ROCK2 (0.44) | ROCK2ROCK1CCR5ALDH1A1MMP1 | |
| SCHEMBL6435174 | 0.91 | MEN1 (0.40) | ROCK2ROCK1CCR5ALDH1A1MMP1 | |
| SCHEMBL6416011 | 0.89 | ROCK2 (0.44) | ROCK2ROCK1CCR5ALDH1A1MMP1 | |
| SCHEMBL6410591 | 0.89 | ROCK2 (0.49) | ROCK2ROCK1CCR5ALDH1A1DRD4 | |
| SCHEMBL6415614 | 0.89 | CCR5 (0.49) | ROCK2ROCK1CCR5ALDH1A1MMP1 | |
| Hydrochloric Acid SCHEMBL6412334 | 0.88 | ROCK2 (0.49) | ROCK2ROCK1CCR5ALDH1A1DRD4 | |
| Hydrochloric Acid SCHEMBL6411285 | 0.88 | CCR5 (0.50) | ROCK2ROCK1CCR5ALDH1A1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | disclosed |
| EP-1499615-A1 | THIENYL COMPOUNDS | AstraZeneca AB (SE) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003087103-A1 | THIENYL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | ROCK2 1735/4885ROCK1 1002/4885CCR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.